Ipamorelin + CJC-1295 Research
Growth Hormone Secretagogue Combination
growth hormone signaling
Rejuvenation
Libido, Hormones and Menopause
Educational information only. Investigational uses may lack FDA approval. Not medical advice or a treatment plan.
This combination pairs Ipamorelin, a selective growth hormone secretagogue, with CJC-1295, a long-acting GHRH analog. The two peptides act at complementary points in the growth hormone axis — Ipamorelin at the pituitary GHSR receptor and CJC-1295 at the GHRH receptor — and are studied together for their synergistic effects on growth hormone pulse signaling and downstream cellular pathways.
Research areas
Synergistic GH Axis Signaling
Research examines how Ipamorelin's GHSR agonism and CJC-1295's GHRH receptor activity interact to amplify growth hormone secretion pulses, exploring their combined downstream effects on IGF-1 signaling and tissue-level receptor pathways.
IGF-1 & Downstream Pathway Research
Studies investigate the combined compound's effects on insulin-like growth factor-1 (IGF-1) production, exploring IGF-1 receptor signaling, cell proliferation pathways, and anabolic signaling research.
Body Composition Signaling
Researchers study effects on lean muscle tissue signaling, fat metabolism pathways, and nitrogen retention research associated with pulsatile growth hormone secretion.
Sleep Architecture & Recovery Research
Studies explore their combined influence on slow-wave sleep signaling, nocturnal growth hormone pulse research, and recovery-related cellular repair pathway investigations.
Metabolic Pathway Research
Research examines downstream effects on glucose metabolism signaling, lipid oxidation pathways, and energy substrate utilization research in the context of growth hormone axis activity.
Investigational compounds. Not FDA-approved. Not medical advice.
Have questions about Ipamorelin + CJC-1295?
Request a free consultation to ask questions and learn more about this research area.
Request a free consultation